The therapeutic promise of biomarker-driven therapies in neuro-oncology was highlighted by a phase I clinical trial that found ivosidenib was well tolerated and resulted in sustained disease stabilization in a subset of patients with IDH1-mutant gliomas. This evidence concerns the gene IDH1 and glioma.